Actively Recruiting
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Led by University of California, San Francisco · Updated on 2025-11-10
300
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the impact of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual differences in patients' symptom experiences will fill this knowledge gap and assist with the early detection of ICI toxicity; guide symptom management; inform treatment decision making; and refine ICI-symptom instrument development. Furthermore, given the limited knowledge in this area, the identification of demographic, clinical, environmental, and molecular risk factors associated with a worse symptom experience is warranted. This is a longitudinal, prospective study evaluating the symptoms that immune checkpoint inhibitors may cause in patients with cutaneous melanoma.
CONDITIONS
Official Title
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years of age or older
- Able to speak and read English
- Diagnosed with stage IIB, III, or IV cutaneous melanoma
- Scheduled to receive one or more immune checkpoint inhibitors at University of California San Francisco medical center locations
- Participants on targeted therapies such as BRAF or MEK inhibitors are eligible
- Provide written informed consent to participate
- Diagnosed with stage IIB or higher cutaneous melanoma
You will not qualify if you...
- Unable to complete study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
E
Erin Hubbard, MPH
CONTACT
C
Carolyn Harris, PhD, RN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here